Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
Dae-Jung KimWayne Huey Herng SheuWook-Jin ChungDaisuke YabeKyoung Hwa HaMasaomi NangakuElise Chia-Hui TanKoichi NodeAtsutaka YasuiWeiyu LeiSunwoo LeeLaura SaarelainenAnouk Deruaz-LuyetMoe H KyawYutaka Seinonull nullPublished in: Journal of diabetes investigation (2023)
The results suggest that both empagliflozin and SGLT2i compared with DPP-4i are associated with a lower risk of cardiovascular events and all-cause mortality in routine clinical care in East Asia.